Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer

Glen J. Weiss, Corey Langer, Rafael Rosell, Nasser Hanna, Frances Shepherd, Lawrence H. Einhorn, Binh Nguyen, Sofia Paul, Patrick McAndrews, Paul A. Bunn, Karen Kelly

Research output: Contribution to journalArticle

139 Scopus citations

Abstract

Purpose: Numerous prospective and retrospective studies have concluded that elderly patients (≥ 70 years old) achieve a similar survival benefit, with acceptable toxicity, from first-line cytotoxic chemotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC) compared with their younger counterparts. However, few published data exist on the efficacy and tolerability of second-line cytotoxic therapy in this population. Patients and Methods: Retrospective analysis of a large second-line trial was performed. Data from 571 patients randomly assigned to docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 every 3 weeks were analyzed for efficacy and toxicity comparisons between age groups and treatment arms. Results: Eighty-six of 571 patients (15%) were ≥ 70 years old, similar to rates of elderly observed in the first-line setting. Elderly patients receiving pemetrexed (n = 47) or docetaxel (n = 39) had a median survival of 9.5 and 7.7 months compared with 7.8 and 8.0 months for younger patients receiving pemetrexed (n = 236) or docetaxel (n = 249), respectively. Elderly patients treated with pemetrexed had a longer time to progression and a longer survival than their counterpart patients treated with docetaxel (not statistically significant). Febrile neutropenia was less frequent in elderly patients treated with pemetrexed (2.5%) compared with docetaxel (19%; P = .025), with only one death as a result of toxicity (docetaxel arm). Conclusion: Elderly patient participation was similar to rates observed in the first-line setting. There was no significant difference in outcome or toxicity between elderly and younger patients. For elderly patients with advanced NSCLC and good performance status, second-line cytotoxic therapy is appropriate. In this subset, pemetrexed produced a more favorable toxicity profile.

Original languageEnglish (US)
Pages (from-to)4405-4411
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number27
DOIs
StatePublished - Sep 20 2006
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this